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Background: Dohaekseunggi-tang (DHSGT) is a traditional plant-based medicine prescribed to promote blood
circulation and to treat obesity and hypertension. The present study aimed to identify potential anti-obesity
activities of DHSGT extract.
Methods: Anti-obesity, anti-hyperlipidemic, and anti-hypertensive effects of orally-administered DHSGT extract were
evaluated in high-fat diet- (HFD)-induced obese mice. Serum biochemistry profiles and expression of diverse metabolic
regulatory gene mRNAs in mouse visceral fat were assessed by RT-PCR. The effects of DHSGT on angiotensin-1 converting
enzyme (ACE) and pancreatic lipase activities were determined using in vitro inhibition assays.
Results: Oral DHSGT treatment reduced obese HFD C57BL/6 J mouse body weight, liver and adipose tissue mass,
adipocyte size, and blood pressure versus untreated HFD mice. DHSGT also decreased serum total cholesterol,
LDL-cholesterol, triglyceride, glucose, and leptin concentrations, and increased HDL-cholesterol and adiponectin
levels in HFD mice. Furthermore, DHSGT markedly increased mRNA expression of peroxisome proliferator activated
receptor-gamma, uncoupling protein-2, and adiponectin in visceral adipose tissue of HFD mice. In vitro tests revealed
that DHSGT effectively inhibited porcine pancreatic lipase and ACE activities, with IC50 values of 7.58 mg/ml and
0.56 mg/ml, respectively.
Conclusions: These results validate traditional knowledge and suggest that DHSGT may be potentially useful for
managing hyperlipidemia, hyperglycemia, hypertension, and obesity.
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Visceral adipose tissueBackground
Obesity is associated with an imbalance between energy
intake and energy expenditure and a subsequent accu-
mulation of excess fat [1]. Obesity is a major risk factor
for metabolic diseases such as hyperlipidemia, hyperten-
sion, atherosclerosis, type 2 diabetes, and fatty liver [2].
Pharmacological agents such as appetite-suppressants,
fat absorption suppressants, and thermogenic drug are
often prescribed for weight loss in treating obesity [3].
Orlistat, which reduces dietary fat absorption by inhibiting
pancreatic lipase, is currently on the global market [4].* Correspondence: hkkim@kiom.re.kr
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unless otherwise stated.Pancreatic lipase is a major enzyme involved in triglyceride
absorption in the intestine, and inhibiting fat absorption
from the diet is a target for treating obesity [5]. However,
these drugs have many limitations due to adverse effects,
such as stomach pain, steatorrhea, and headaches [6].
Recently, the high prevalence of obesity and associated
complications such as hypertension has led to in-
creased research in traditional herbal medicines that
have negligible adverse effects, as alternative weight-
loss therapies [7].
In symptom-based Oriental medicine, the underlying
treatment mechanism of obesity is accomplished as follows:
remove dampness, dispel phlegm, induce diuresis, remove
internal heat, promote digestion and remove food stag-
nancy, restore the normal flow of the liver Qi (vital energy),td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(DHSGT) (Taohe Chengqi Tang: Chinese), is a tra-
ditional medicine prescribed for oral administration to
drain heat and promote blood flow to eliminate blood
stasis [10]. In Korea, it is mainly prescribed to treat
obesity and hypertension caused by stagnation of phlegm-
dampness and blood stasis [3,11]. DHSGT has also been
documented to treat diabetes mellitus, chronic pyelo-
nephritis, chronic hepatitis, acute necrotic enteritis, and
amenorrhea [12] .This prescription is an herbal mixture
composed of Glycyrrhizae uralensis Fischer (Chinese
licorice), Rheum undulatum Linne (a rhubarb relative),
Prunus persica L. (peach tree), and Cinnamomum cassia
Presl (Chinese cinnamon, an evergreen tree) [13]. Re-
cently, DHSGT was reported to ameliorate diabetic ath-
erosclerosis in western diet-fed apolipoprotein E knockout
(ApoE KO) mice [14]. Treatment with DHSGT in western
diet-fed ApoE KO mice also reduced LDL cholesterol,
triglyceride, and glucose levels as well as blood pressure
[14]. In high-fat diet-induced obese rats, DHSGT de-
creased the body weight, liver and adipose tissue weights,
and serum triglyceride levels [15]. DHSGT also decreased
plasma glucose, cholesterol, triglyceride, and LDL choles-
terol levels in high-fat/high-cholesterol diet-fed db/db mice
[16]. These results show that DHSGT may be useful in
the treatment of obesity and metabolic disease. However,
DHSGT effects and mechanisms of action in treating
obesity remain obscure. Here, we investigated the poten-
tial anti-obesity and anti-hypertensive effects of DHSGT
using a high-fat diet-induced mouse model and in vitro
assays to evaluate possible DHSGT inhibition of pancre-




The herbs were purchased from Kwangmyeongdang Me-
dicinal Herbs Co. (Ulsan, Korea) and authenticated based
on their microscopic and macroscopic characteristics by
the Classification and Identification Committee of the
Korea Institute of Oriental Medicine (KIOM). The for-
mula for DHSGT consists of five herbs including Glycyr-
rhizae uralensis Fischer (40 g), Rheum undulatum Linne
(80 g), Prunus persica Linne (60 g), Cinnamomum cassia
Presl (40 g), and Natrii Sulfas (40 g) mixed. The DHSGT
(260 g) was boiled with distilled water (1:10, v/v) at 100°C
for 2 h, and the extract was filtered, lyophilized, and subse-
quently stored at −20°C. The yield of DHSGT aqueous
extract was 11.25% (w/w).
Animals and experimental diets
Male, 8-week-old C57BL/6 J mice were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). They
were housed in an air-conditioned room with a 12-hlight/12-h dark cycle at a temperature of 21 ± 2°C and
humidity of 50 ± 5%, and were fed a commercial diet
(Ralston-Purina, St. Louis, MO, USA) for 1 week. Mice
were provided with a laboratory diet and water ad libi-
tum. For inducing obesity, the mice were fed a high-fat
diet (Rodent Diet D12492; Research Diets, Inc., New
Brunswick, NJ, USA), providing 60% of energy as fat,
20% as protein, and 20% as carbohydrates. Non-obese
control mice were fed a commercial standard chow diet
(Orient Bio Inc., Seongnam, Korea) consisting of 14%
energy as fat, 21% as protein, and 65% as carbohydrates.
The mice were randomly divided into three groups (n = 5),
and respectively fed a normal diet (Control), a high-fat
diet (HFD) and a high-fat diet plus DHSGT (HFD-
DHSGT) for 7 weeks. DHSGT was dissolved in normal
saline, and was orally administered to the mice
(200 mg/kg/day). The Control and HFD mice received
vehicle (normal saline) only. Body weight and food intake
were monitored every week. This study adhered to the
Guide for the Care and Use of Laboratory Animals devel-
oped by the Institute of Laboratory Animal Resources of
the National Research Council, and was approved by the
Institutional Animal Care and Use Committee of Daejeon
University in Daejeon, Korea.Biochemical serum assay
At the end of the experiment period, the mice were
anesthetized with ether after an overnight fast. Blood was
withdrawn from the abdominal aorta into a vacuum tube.
Biochemical analyses of concentrations of total choles-
terol, HDL cholesterol, LDL cholesterol, triglyceride,
glucose, creatinine, aspartate aminotransferase (AST),
and alanine aminotransferase (ALT) were determined using
an automatic analyzer (Express Plus; Chiron Diagnostics,
East Walpole, MA, USA). Serum insulin, leptin, and
adiponectin levels were measured by immunoassay
(ELISA) using commercially available kits (Linco Research
Inc., St. Charles, MO, USA).Weight and histology analysis of adipose tissues and liver
After blood collection, the white adipose tissues (sub-
cutaneous and visceral fat) and liver were removed from
each mouse and weighed. For adipocyte staining, visceral
adipose tissue was fixed in 10% neutral-buffered forma-
lin solution for 1 day, paraffin-embedded, sectioned to a
thickness of 6 μm, and stained with hematoxylin and
eosin. To quantitate adipocyte size, the stained sections
were analyzed using light microscopy (Olympus BX51,
Olympus Optical Co., Tokyo, Japan) and image analysis
software (Image-Pro Plus version 5.0; Media Cybernetics,
Silver Spring, MD, USA).
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Total RNA from visceral adipose tissue was isolated with
TRI reagent® (Sigma-Aldrich, St. Louis, MO, USA) and
digested with DNase I (Life Technologies, Grand Island,
NY, USA) to remove chromosomal DNA. Five micrograms
of total RNA was reverse transcribed into cDNA with the
First Strand cDNA Synthesis kit (Amersham Pharmacia,
Piscataway, NJ, USA). Real-time quantitative PCR was per-
formed using the Applied Biosystems 7500 Real-Time PCR
system (Applied Biosystems, Grand Island, NY, USA). The
primer sequences and the probe-sequence are shown in
Table 1. Probes were labeled with the fluorescent reporter
6-carboxy-fluorescein. Aliquots of sample cDNAs and an
equal amount of beta-actin cDNA were amplified with
the TaqMan® Universal PCR master mixture containing
DNA polymerase according to manufacturer instructions
(Applied Biosystems, Foster, CA, USA). PCR conditions
were 2 min at 50°C, 10 min at 95°C, 15 s at 95°C, and
1 min at 60°C for 40 cycles. The concentration of
target gene was determined using the comparative Ct
(threshold cycle number at cross-point between amplifica-
tion plot and threshold) method, according to manufac-
turer instructions.
Blood pressure measurement
Blood pressure was determined by a tail-cuff method
using the CODA™ noninvasive blood pressure cuff system
(Kent Scientific Corp., Torrington, CT, USA).
Pancreatic lipase activity inhibition assay
The ability of DHSGT to inhibit pancreatic lipase activ-
ity was measured using the QuantiChrom™ lipase assay
kit (BioAssay Systems, Hayward, CA, USA). The colorimet-
ric enzyme assay is based on the dimercaptopropanol
tributyrate (BALB) and 5,5′-dithiobis 2-nitrobenzoic
acid (DTNB) method of Furukawa et al. [17]. DHSGT
was dissolved in water and serially diluted. After incubat-
ing 10 ul of DHSGT sample solution at different concen-
trations (0, 0.5, 1, 2, 6.25, 12.5 or 25 mg/ml) or water












GAPDH VIC 5′-TGCATCCTGCACCACCAACTGCTTAG-3′lipase solution (50 units/ml) with 140 ul of working so-
lution for 10 min and 20 min at room temperature, sample
absorbance was measured at 412 nm using a microplate
reader (Multiskan® GO; Thermo Fisher Scientific, Hudson,
NH, USA). The working solution was prepared by the
addition of 5 mg color DTNB reagent and 8 ul sub-
strate BALB solution (20 mM BALB in ethanol) in 140 ul
Tris buffer (100 mM Tris–HCl and 5 mM CaCl2, pH 8.5).
Lipase activity was determined by measuring the SH group
formed from lipase cleavage of BALB react with DTNB
to yellow colored product. Orlistat (0, 0.01, 0.1, 0.5 or
1 mg/ml) was used as the positive control. Lipase inhib-
ition (%) was calculated according the following formula:
Inhibition activity (%) = {[OD (20 min-10 min)control-OD
(20 min-10 min)sample] / OD (20 min-10 min)control} × 100.
The IC50 value was defined as the concentration of inhibi-
tor required to inhibit 50% of pancreatic lipase activity.
ACE activity inhibition assay
ACE activity was measured using the K-assay® ACE in-
hibition kit (Kamiya Biomedical Co., Seattle, WA, USA).
DHSGT was dissolved in water and serially diluted.
Twenty μl of DHSGT sample solution at different con-
centrations (0, 0.03, 0.06, 0.125, 0.25, 0.5, 1 or 2 mg/ml) or
water (control, no inhibition) were added to 20 μl of 3HB-
GGG substrate buffer (0.69 mM 3-hydroxybutyryl-Gly-
Gly-Gly in 50 mM HEPES, pH 8.3). Twenty μl of ACE
enzyme working solution (25 units/ml) was then added
and the mixture was incubated at 37°C for 60 min.
Then, 200 μl of indicator WST (a water soluble tetrazo-
lium dye) solution was added to the reaction mixture
and incubated at room temperature for another 10 min.
The absorbance at 450 nm was measured the amount of
cleaved 3-hydroxybutyric acid (3HB) from 3HB-GGG using
a microplate reader. Captopril at same concentrations was
used as positive control. ACE inhibition (%) was calculated
according the following formula: Inhibition activity (%) =
[(ODcontrol-ODsample) / ODcontrol] × 100. The IC50 value was
defined as the concentration of inhibitor required to inhibit
50% of ACE activity.
Statistical analysis
Data were analyzed by one-way analysis of variance followed
by Duncan’s multiple-range tests. All data are presented as
means ± SE. Significant differences were accepted when the
p-value was <0.05.
Results
Changes of body weight, food intake and food efficiency
ratio
Body weight, body weight gain, food intake, and food ef-
ficiency ratio of the mice fed the HFD with oral treatment
of DHSGT for 7 weeks shown in Figure 1A and Table 2.
The final body weight of mice fed the HFD was higher
Figure 1 Effect of DHSGT on body weight and adipocyte size in HFD-induced obese mice. (A) Body weight in obese mice fed HFD for
7 weeks. (B) Adipocyte area, and (C) representative images of hematoxylin and eosin-stained visceral fat sections (original magnification 400×).
Values are expressed as means ± SEM (n = 5 animals/group). Significant differences were observed between the Control and HFD groups: ##,
p < 0.01; ###, p < 0.001. Significant differences were observed between the HFD and HFD-DHSGT groups: **, p < 0.01; ***, p < 0.001. HFD, high-fat diet;
DHSGT, Dohaekseunggi-tang.
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ment reduced body weight compared to the high- fat diet
group. Body weight gain was significantly decreased in the
DHSGT treated group compared to the HFD control group.
DHSGT did significantly not affect food intake. FoodTable 2 Effects of DHSGT on body weight, food intake, food-e
Control
Final body weight, g 28.40 ± 0.51
Body-weight gain, g/day 0.09 ± 0.01
Food intake, g/day 3.36 ± 0.00
Food-efficiency ratio (%) 2.64 ± 0.31
White adipose-tissue weight
Subcutaneous, g 0.29 ± 0.08
Visceral, g 0.28 ± 0.03
Liver weight, g 1.04 ± 0.07
Food-efficiency ratio (%) = (body-weight gain/food intake) × 100. Values are express
**p < 0.01; ***, p < 0.001 compared with the HFD group.efficiency ratio (FER) was higher in the HFD group than in
the Control group, and the FER was significantly decreased
in the DHSGT-treated group versus the HFD group. These
results indicate that the DHSGT treatment efficiently re-
duces body weight increases caused by the high-fat diet.fficiency ratio, and tissue weight
HFD HFD-DHSGT
41.40 ± 0.68### 31.60 ± 1.47***
0.37 ± 0.02### 0.17 ± 0.04***
2.69 ± 0.00 2.24 ± 0.00
13.60 ± 0.57### 7.53 ± 1.58**
1.92 ± 0.12### 0.93 ± 0.45**
3.79 ± 0.27### 1.46 ± 0.30***
1.12 ± 0.04 0.85 ± 0.06**
ed as means ± SEM (n = 5); ###, p < 0.001 compared with the Control group;
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To investigate whether DHSGT decreases adiposity, fat
tissues and liver were removed from mice and weighed.
Subcutaneous and visceral fat weights were increased in
the HFD mice by 6.6 and 13.5-fold, respectively, versus
Control mice, and this effect was significantly mitigated
by treating HFD mice with DHSGT (Table 2). Liver
weight was decreased in the HFD-DHSGT treated mice
versus HFD mice (Table 2).Biochemical determinations in serum
Serum biochemical profiles of all three mouse groups after
receiving their respective diets for 7 weeks are shown
in Table 3. The triglyceride, total cholesterol, and LDL-
cholesterol levels of mice fed the high-fat diet were
higher than those of mice fed the normal diet. DHSGT
treatment significantly suppressed serum lipid concen-
tration increases in HFD mice. Glucose levels in HFD
mice were higher than those of mice fed the normal
diet, and DHSGT treatment significantly suppressed
HFD-induced serum glucose elevation, to levels approxi-
mating those in untreated Control mice. However, HDL-
cholesterol concentrations were not significantly different
between the HFD and HFD-DHSGT groups.
To evaluate potential toxic effects of ingesting DHSGT,
serum markers that indicate liver and kidney damage were
measured at the end of the experimental period (Table 3).
Creatinine levels were significantly decreased in the HFD-
DHSGT mice versus levels in HFD mice. Serum levels of
AST and ALT were increased in HFD mice compared to
Control mice. Levels of ALT were significantly decreased
in the HFD mice by DHSGT-treatment mice but AST
levels were not significantly affected by DHSGT-treatment
in HFD mice.Table 3 Biochemical measurements in mouse serum
Control HFD HFD-DHSGT
Total cholesterol, mg/dl 98.6 ± 3.7 163.2 ± 13.3## 130.2 ± 4.4*
Triglyceride, mg/dl 27.0 ± 1.3 33.4 ± 1.8# 27.4 ± 1.5*
LDL cholesterol, mg/dl 6.4 ± 0.7 13.8 ± 1.4## 7.0 ± 0.4**
HDL cholesterol, mg/dl 63.0 ± 0.8 75.0 ± 2.7## 69.8 ± 2.3
Glucose, mg/dl 134.8 ± 3.00 200.2 ± 11.5## 144.4 ± 19.3*
AST, U/l 80.8 ± 4.3 112.6 ± 10.4# 86.8 ± 5.3
ALT, U/l 39.6 ± 2.4 58.2 ± 3.7 ## 32.0 ± 3.9**
Creatinine, mg/dl 0.142 ± 0.015 0.172 ± 0.009 0.140 ± 0.008*
Leptin, ng/ml 0.14 ± 0.02 7.35 ± 0.46 ### 1.50 ± 1.12***
Adiponectin, ng/ml 1.39 ± 0.24 3.61 ± 0.29### 13.46 ± 2.43***
Values are expressed as means ± SEM (n = 5). #, p < 0.05; ##, p < 0.01; ###,
p < 0.001 compared with the Control group; *, p < 0.05; **, p < 0.01; **, p < 0.01
compared with the HFD group.Adipocytokine serum concentrations
Mice fed the HFD displayed approximately 50-fold in-
creased serum leptin levels versus Control mice (Table 3).
Treatment of HFD mice with DHSGT decreased HFD-
induced serum leptin by approximately 80%. Serum adi-
ponectin was increased less than 2-fold in HFD mice versus
normal-diet Control mice. Treatment of HFD mice with
DHSGT caused an additional increase in serum adiponec-
tin, to levels nearly four-fold higher than levels measured in
HFD-only mice (Table 3).
Histology of adipose tissue
Average visceral fat adipocyte size (area) in HFD mice
was significantly larger (approximately10-fold) than in
normal-diet Control mice (Figure 1B and C). When HFD
mice were treated with DHSGT, adipocyte size was signifi-
cantly decreased by over 50%. These results indicate that
DHSGT-induced reduction in fat mass was partly due to
decreased visceral fat adipocyte size.
Expression of genes involved in lipid metabolism
To understand the mechanism of DHSGT effects on lipid
metabolism, we investigated expression of lipogenesis- or
lipolysis-related genes in visceral fat (Figure 2). The HFD
increased leptin mRNA expression versus Control mice
and DHSGT-treatment decreased HFD-induced leptin
mRNA by >50% (Figure 2A). While HFD mice expressed
similar adiponectin mRNA levels versus Control mice,
DHSGT-treatment of HFD mice significantly increased
adiponectin (Figure 2B). Peroxisome proliferator activated
receptor-γ (PPAR-γ) mRNA expression was significantly
increased in HFD mice versus Control mice, and was
further increased by DHSGT-treatment of HFD mice
(Figure 2C). Expression of mitochondrial uncoupling
protein-2 (UCP-2) mRNA, a molecule involved in fat
metabolism, was not affected by HFD alone, but was
markedly upregulated in HFD mice that were concomi-
tantly treated with DHSGT (Figure 2D).
Pancreatic lipase inhibition
The DHSGT extract exhibited pancreatic lipase inhibitory
activity in a concentration-dependent manner (Figure 3A).
DHSGT at 25 mg/ml inhibited pancreatic lipase activity by
92.28%, while orlistat (1 mg/ml, positive control) inhibited
75.38% of the enzyme activity (Figure 3B). The IC50 values
of DHSGT extract and orlistat were 7.58 mg/ml and
0.33 mg/ml, respectively.
ACE inhibition
ACE activity was inhibited by DHSGT extract in a
concentration-dependent manner (Figure 4). Two mg/ml
DHSGTcaused 77.06% inhibition, while 2 mg/ml captopril
(positive control) caused 85.78% inhibition. The ACE
Figure 2 Effect of DHSGT on mRNA expression of leptin, adiponectin, PPAR-γ, and UCP-2 in visceral adipose tissue of HFD-induced
obese mice. Expression levels of (A) leptin, (B) adiponectin, (C) PPAR-g, and (D) UCP-2. Values are expressed as means ± SEM (n = 5 animals/group).
Significant differences were observed between the Control and HFD groups: ##, p < 0.01; ###, p < 0.001. Significant differences were observed between
the HFD and HFD-DHSGT groups, respectively: **, p < 0.01; ***, p < 0.001. DHSGT, Dohaekseunggi-tang; PPAR-γ, peroxisome proliferator activator
receptor-γ; UCP-2, mitochondrial uncoupling protein-2, HFD, high-fat diet.
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while captopril had an IC50 value <0.03 mg/ml (Figure 4).
Effect of DHSGT on blood pressure
Systolic, diastolic, and mean blood pressure measurements
were all markedly upregulated in HFD mice versus normal-
diet control mice (Table 4). All three parameters were
significantly decreased in HFD mice that concurrently
received DHSGT treatment.
Discussion
Adipose tissue is a dynamic organ that plays an important
role in energy balance and body mass changes throughout
an individual’s lifetime, in response to the metabolic re-
quirements of the organism [18]. This study investigated
the effects of DHSGT on HFD-induced fat accumulation
in the adipose tissue of mice. In mice made obese by feed-
ing a high-fat diet, DHSGT treatment inhibited white
adipose tissue accumulation and adipocyte enlargement,
and, decreased body-weight gain and serum total choles-
terol, LDL-cholesterol, triglyceride, and glucose levels.
Adipocytes secrete various adipocytokines such as tumor
necrosis factor-α, leptin, adiponectin, and resistin [19]. Adi-
ponectin plays important roles in insulin sensitivity and
fatty acid oxidation, and adiponectin levels are negatively
correlated with body fat mass, and serum glucose, insulin,
and triglyceride levels [20]. Leptin levels in human androdent are directly associated with adiposity and body-
weight changes [21]. In this study, both the serum adi-
ponectin protein levels and adipocyte adiponectin mRNA
levels were markedly increased in DHSGT-treated obese
mice, whereas leptin expression in serum and adipose
tissues was decreased by DHSGT treatment. These results
suggest that improved adipocytokines levels by DHSGT
treatment may be contribute to decreased body weight,
body fat accumulation, and serum levels of glucose, chol-
esterol, and triglycerides. Obesity due to adipocyte hyper-
trophy leads to changes in adipocytokine profiles involved
in the development of insulin resistance, as well as in the
production of signaling molecules, such as PPAR-γ, aP2,
and leptin [22]. PPAR-γ is a transcription factor promin-
ently expressed in adipose tissue, and it activates adipocyte
differentiation [23]. Moreover, exposure of mice to high
fat diet increases adipose tissue expression of PPAR-γ [24].
Our result also showed that the HFD-induced obese mice
expressed higher mRNA levels of PPAR-γ then the normal
control mice: however, these effects were weaker than
that of the DHSGT-treated mice. In this study, feeding
the HFD produced slight increases in serum adiponectin
levels. Circulating adiponectin levels were known to
be modulated by PPAR-γ [25]. Thus, the increases of
adiponectin levels in serum of HFD mice may be me-
diated by the up-regulation of PPAR-γ. Treatment with
DHSGT increased mRNA expression of PPAR-γ and UCP-
Figure 3 Inhibitory effect of DHSGT on in vitro porcine pancreatic
lipase activity. (A) Pancreatic lipase inhibitory activity at different
concentration of DHSGT. (B) Orlistat was used as a positive control.
Values are expressed as means ± SEM of three independent experiments.
DHSGT, Dohaekseunggi-tang.
Figure 4 Inhibitory effect of DHSGT on angiotensin 1-
converting enzyme in vitro. Captopril was used as a positive
control. Values are expressed as means ± SEM of three independent
experiments. DHSGT, Dohaekseunggi-tang.
Table 4 Effects of DHSGT on blood pressure
Control HFD HFD-DHSGT
Blood pressure
Systolic, mmHg 65.36 ± 6.30 170.56 ± 06.33### 86.56 ± 7.39***
Diastolic, mmHg 61.14 ± 4.97 167.00 ± 05.80### 82.33 ± 7.26***
Mean, mmHg 62.43 ± 5.25 101.11 ± 13.57### 83.67 ± 7.22*
Values are expressed as means ± SEM (n = 5 animals per group). ###, p < 0.001
compared with the Control group; *, p < 0.05; ***, p < 0.001 compared with the
HFD group.
Sung et al. BMC Complementary and Alternative Medicine 2014, 14:372 Page 7 of 9
http://www.biomedcentral.com/1472-6882/14/3722 in visceral adipose tissue. Thiazolidinediones (TZDs)
improve insulin sensitivity through PPAR-γ, and TZD
treatment in obese humans increases adiponectin levels
[26]. In rodent disease models, PPARγ agonists prevent
increased adiposity and body weight, and improve insu-
lin resistance and dyslipidemia [27]. DHSGT treatment
restored decreased PPAR-γ expression levels in the aorta
of western diet-fed ApoE KO mice and the beneficial
effect of DHSGT on endothelial dysfunction in diabetic
atherosclerosis was similar to rosiglitazone (a PPARγ
agonist) which is ameliorated in insulin sensitivity [14].
UCP-2 plays an important role in fat metabolism by pro-
moting fatty acid oxidation in white adipose tissue and
reducing body-weight gain [28]. Decreased fat accumu-
lation and serum lipid levels by DHSGT treatment are
possibly mediated by increased expression of these regula-
tory genes.Pancreatic lipase is a key enzyme that hydrolyzes 50-
70% of total dietary fat in the digestive system, convert-
ing triglycerides to monoglycerides and free fatty acids
[7,29]. Inhibiting pancreatic lipase is an important strat-
egy for treating obesity and other metabolic disorders. In
this study, DHSGT inhibited pancreatic lipase activity in
a concentration-dependent manner, with an IC50 value of
7.58 mg/ml. The lipase inhibitory activity of DHSGT may
be able to suppress dietary fat absorption in vivo, too.
Obesity is a worldwide disease that is often accompanied
by several metabolic abnormalities such as hyperten-
sion, hyperglycemia, and dyslipidemia [30]. The renin-
angiotensin-aldosterone system (RAAS) is a major
mediator of hypertension. The RAAS system produces
angiotensin II from angiotensin I, and angiotensinogen via
renin and ACE [31]. Additionally, ACE metabolizes and
inactivates the vasodilator bradykinin. Thus, ACE has dual
roles of increasing vasoconstriction and inactivating vaso-
dilation [32]. DHSGT showed potent inhibitory activity
against ACE in vitro, with an IC50 value of 0.56 mg/ml,
and it decreased the high blood pressure induced by
increasing dietary fat in the HFD mouse group. This indi-
cates a potential anti-hypertensive effect of DHSGT. Acti-
vation of the RAAS is common in obesity [33]. Increased
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promotes inflammation, lipogenesis and reactive oxy-
gen species generation, and impairs insulin signaling,
all of which worsen the adipose environment [34]. Thus,
RAAS pathway blockade by inhibiting ACE activity is one
goal in treating the hypertension characteristic of metabolic
syndrome and obesity. This study evaluated the ACE in-
hibitory effects of DHSGT extract using an in vitro model.
For natural products to inhibit ACE, they first need to
be absorbed in the blood and then act ACE. Since we
are evaluating a blend of herbal extracts that contains
numerous bioactive compounds, further study is needed
to identify and evaluate the active ACE inhibitory com-
pounds in the DHSGT extract.
Conclusions
DHSGT treatment ameliorates body-weight gain, adipose
tissue accumulation, hypertension, and dysregulated serum
lipid profiles in HFD-induced obese mice by improving
lipid metabolism. Our in vitro assay showed that DHSGT
is an effective inhibitor of pancreatic lipase and ACE
activity. These findings validate traditional knowledge
and suggest that DHSGT may potentially be useful for
managing hyperlipidemia, hyperglycemia, hypertension,
and obesity. Thus, further study will be performed to
identify and characterize the bioactive components re-
sponsible for its anti-obesity and anti-hypertensive effects.
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